Brokers Set Expectations for KYTX Q3 Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – William Blair issued their Q3 2025 earnings estimates for Kyverna Therapeutics in a report issued on Wednesday, August 20th. William Blair analyst S. Corwin forecasts that the company will post earnings of ($0.99) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share. William Blair also issued estimates for Kyverna Therapeutics’ Q4 2025 earnings at ($1.04) EPS, FY2025 earnings at ($4.04) EPS, FY2026 earnings at ($4.21) EPS and FY2027 earnings at ($3.54) EPS.

Kyverna Therapeutics (NASDAQ:KYTX) last released its earnings results on Tuesday, August 12th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.03.

Separately, HC Wainwright raised shares of Kyverna Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $4.00 to $5.00 in a report on Tuesday, May 27th. One analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. Based on data from MarketBeat.com, Kyverna Therapeutics has an average rating of “Buy” and a consensus price target of $15.60.

Kyverna Therapeutics Stock Performance

KYTX stock opened at $3.85 on Friday. Kyverna Therapeutics has a one year low of $1.78 and a one year high of $8.78. The company’s fifty day moving average price is $3.46 and its 200-day moving average price is $2.80. The company has a market capitalization of $166.50 million, a PE ratio of -1.05 and a beta of 3.05.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. lifted its position in shares of Kyverna Therapeutics by 2,225.0% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 461,959 shares of the company’s stock valued at $1,728,000 after buying an additional 442,090 shares during the last quarter. Peapod Lane Capital LLC purchased a new position in shares of Kyverna Therapeutics in the 1st quarter valued at approximately $765,000. TD Asset Management Inc raised its position in Kyverna Therapeutics by 179.5% during the 2nd quarter. TD Asset Management Inc now owns 252,196 shares of the company’s stock worth $774,000 after buying an additional 161,954 shares during the last quarter. Integral Health Asset Management LLC increased its holdings in shares of Kyverna Therapeutics by 75.0% during the 4th quarter. Integral Health Asset Management LLC now owns 350,000 shares of the company’s stock valued at $1,309,000 after purchasing an additional 150,000 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Kyverna Therapeutics by 21.7% during the 4th quarter. Geode Capital Management LLC now owns 539,682 shares of the company’s stock valued at $2,019,000 after purchasing an additional 96,370 shares in the last quarter. 18.08% of the stock is currently owned by institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.